Biotech | July 10, 2022
WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Site Enhances New Modality CRDMO Platform Capacity for Customers
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Subscribe To Our Newsletter & Stay Updated
